Supercomputer Research Leads to Human Trial of Potential COVID-19 Therapeutic Raloxifene

By Oliver Peckham

October 29, 2020

Six months of patient trials with the ostensible COVID-19 therapeutic remdesivir have cast serious doubt on its ability to even reduce the severity of COVID-19, let alone reliably reduce patient mortality. This has left medical professionals once again without a proven COVID-19 therapeutic as the pandemic shows signs of reaching unprecedented spikes in Europe and North America. As the world confronts the possibility of a dark winter, a supercomputer-powered pharmaceutical research coalition based in Italy is producing a glimmer of light: a repurposed drug called raloxifene, identified by supercomputing research, that will now be entering clinical trials to test its efficacy as a therapeutic for COVID-19.

The coalition in question is Exscalate4CoV, a public-private partnership spanning 50 partners across seven European countries (Belgium, Germany, Italy, Poland, Spain, Sweden and Switzerland). Led by Italian pharmaceutical firm Dompé, Exscalate4CoV leverages Dompé’s “exascale smart platform against pathogens” (Exscalate) and its accompanying chemical library of half a billion molecules in service of one goal: drug development for COVID-19.

Included in these 50 partners are an armada of supercomputer centers across Europe: CINECA in Italy; Barcelona Supercomputing Center (BSC) in Spain; Jülich Supercomputing Centre in Germany; and the KTH supercomputing center in Sweden. In total, the coalition claims it has access to “around 120 petaflops” of supercomputing power.

Finding raloxifene

Exscalate4CoV formed in mid-February, mere weeks before Italy was set to become the first true epicenter of the pandemic outside of China – and by early March, it had been awarded €3 million by the European Commission for COVID-19 research. As the pandemic raged across Europe, Exscalate4CoV began crunching Exscalate’s enormous molecular library.

The HPC5 system. Image courtesy of Eni.

Within a few months after that award, the consortium had tested over 400,000 molecules for their ability to dock with SARS-CoV-2’s viral proteins. This screening work was performed on four leading European supercomputers: oil and gas firm ENI’s private HPC5 system (51.7 peak petaflops); CINECA’s Marconi-100 system (29.4 peak petaflops); BSC’s MareNostrum 4 system (13.7 peak petaflops); and Jülich’s Juwels system (12 peak petaflops, soon to dramatically increase).

The raloxifene molecule.

After whittling those 400,000 molecules down to 7,000 that were tested in vitro, Exscalate4CoV identified one particularly promising preexisting pharmaceutical: raloxifene, a generic drug designed to help treat and prevent osteoporosis in postmenopausal women. Exscalate4CoV theorized that raloxifene might be able to halt the spread of the virus in mildly symptomatic COVID-19 patients by using estrogen as a defense.

“The selected drug is well-tolerated, has a well-known toxicological profile in the clinic and has shown great efficacy in in vitro experimentation,” said David Vannozzi, director of CINECA, at the time. “Now, we move on to in vivo experimentation, on animals and then on humans.”

The final test

The National Institute for Infectious Diseases in Rome.

Now, over four months later, the time for human trials has come. Exscalate4CoV has announced that, as a result of its research, AIFA (the Italian pharmaceutical regulatory agency) has greenlit a clinical trial of raloxifene. The study, based at the National Institute for Infectious Diseases in Rome and the Humanitas Research Hospital in Milan, will consist of up to 450 participants split into three treatment groups. The participants will be administered a seven-day course of either raloxifene or a placebo, after which they will be monitored for 12 weeks. Researchers will be assessing whether raloxifene safely and efficiently blocks the replication of the SARS-CoV-2 virus in human cells.

“It inhibits virus replication, thus preventing the worsening of patients with mild symptoms, and also decreases infectivity, limiting the viral load,” Marco Allegretti, head of research at Dompé, told Reuters. To that end, Dompé, the Fraunhofer Institute and the University Leuven filed a patent for the use of raloxifene in early May “in order to promote universal access to treatment,” which the consortium stressed is core to its founding principles.

Despite the promising research, Exscalate4CoV cautioned that the drug is not licensed for use in this manner outside of clinical studies as, to date, there is no conclusive evidence that raloxifene carries more benefits than risks when used with COVID-19 patients, nor is there evidence on effective dosage amounts. (In short: don’t try this at home.)

Exscalate4CoV’s ongoing research

The raloxifene research is far from the only work emerging from Exscalate4CoV. In addition to the data from its massive molecular docking initiative and over 20,000 in vitro experiments, the consortium already has ten finalized peer-reviewed articles, with ten more approaching finalization. This research, of course, is open access, with the papers available here and the data available here. Finally, the consortium is currently evaluating two additional drugs for use as COVID-19 therapeutics.

These results (and the ensuing ongoing studies) are the product of now-complete phase one of Exscalate4CoV, which aimed to identify promising molecules for those already infected with COVID-19. The second phase will aim to identify molecules capable of inhibiting future infections.

To learn more about Exscalate4CoV’s coronavirus research, listen to or read HPCwire’s interview with CINECA’s Carlo Cavazzoni, conducted at the height of Italy’s battle with COVID-19.

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industry updates delivered to you every week!

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion XL — were added to the benchmark suite as MLPerf continues Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing power it brings to artificial intelligence.  Nvidia's DGX Read more…

Call for Participation in Workshop on Potential NSF CISE Quantum Initiative

March 26, 2024

Editor’s Note: Next month there will be a workshop to discuss what a quantum initiative led by NSF’s Computer, Information Science and Engineering (CISE) directorate could entail. The details are posted below in a Ca Read more…

Waseda U. Researchers Reports New Quantum Algorithm for Speeding Optimization

March 25, 2024

Optimization problems cover a wide range of applications and are often cited as good candidates for quantum computing. However, the execution time for constrained combinatorial optimization applications on quantum device Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at the network layer threatens to make bigger and brawnier pro Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HBM3E memory as well as the the ability to train 1 trillion pa Read more…

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing po Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HB Read more…

Nvidia Looks to Accelerate GenAI Adoption with NIM

March 19, 2024

Today at the GPU Technology Conference, Nvidia launched a new offering aimed at helping customers quickly deploy their generative AI applications in a secure, s Read more…

The Generative AI Future Is Now, Nvidia’s Huang Says

March 19, 2024

We are in the early days of a transformative shift in how business gets done thanks to the advent of generative AI, according to Nvidia CEO and cofounder Jensen Read more…

Nvidia’s New Blackwell GPU Can Train AI Models with Trillions of Parameters

March 18, 2024

Nvidia's latest and fastest GPU, codenamed Blackwell, is here and will underpin the company's AI plans this year. The chip offers performance improvements from Read more…

Nvidia Showcases Quantum Cloud, Expanding Quantum Portfolio at GTC24

March 18, 2024

Nvidia’s barrage of quantum news at GTC24 this week includes new products, signature collaborations, and a new Nvidia Quantum Cloud for quantum developers. Wh Read more…

Alibaba Shuts Down its Quantum Computing Effort

November 30, 2023

In case you missed it, China’s e-commerce giant Alibaba has shut down its quantum computing research effort. It’s not entirely clear what drove the change. Read more…

Nvidia H100: Are 550,000 GPUs Enough for This Year?

August 17, 2023

The GPU Squeeze continues to place a premium on Nvidia H100 GPUs. In a recent Financial Times article, Nvidia reports that it expects to ship 550,000 of its lat Read more…

Shutterstock 1285747942

AMD’s Horsepower-packed MI300X GPU Beats Nvidia’s Upcoming H200

December 7, 2023

AMD and Nvidia are locked in an AI performance battle – much like the gaming GPU performance clash the companies have waged for decades. AMD has claimed it Read more…

DoD Takes a Long View of Quantum Computing

December 19, 2023

Given the large sums tied to expensive weapon systems – think $100-million-plus per F-35 fighter – it’s easy to forget the U.S. Department of Defense is a Read more…

Synopsys Eats Ansys: Does HPC Get Indigestion?

February 8, 2024

Recently, it was announced that Synopsys is buying HPC tool developer Ansys. Started in Pittsburgh, Pa., in 1970 as Swanson Analysis Systems, Inc. (SASI) by John Swanson (and eventually renamed), Ansys serves the CAE (Computer Aided Engineering)/multiphysics engineering simulation market. Read more…

Choosing the Right GPU for LLM Inference and Training

December 11, 2023

Accelerating the training and inference processes of deep learning models is crucial for unleashing their true potential and NVIDIA GPUs have emerged as a game- Read more…

Intel’s Server and PC Chip Development Will Blur After 2025

January 15, 2024

Intel's dealing with much more than chip rivals breathing down its neck; it is simultaneously integrating a bevy of new technologies such as chiplets, artificia Read more…

Baidu Exits Quantum, Closely Following Alibaba’s Earlier Move

January 5, 2024

Reuters reported this week that Baidu, China’s giant e-commerce and services provider, is exiting the quantum computing development arena. Reuters reported � Read more…

Leading Solution Providers

Contributors

Comparing NVIDIA A100 and NVIDIA L40S: Which GPU is Ideal for AI and Graphics-Intensive Workloads?

October 30, 2023

With long lead times for the NVIDIA H100 and A100 GPUs, many organizations are looking at the new NVIDIA L40S GPU, which it’s a new GPU optimized for AI and g Read more…

Shutterstock 1179408610

Google Addresses the Mysteries of Its Hypercomputer 

December 28, 2023

When Google launched its Hypercomputer earlier this month (December 2023), the first reaction was, "Say what?" It turns out that the Hypercomputer is Google's t Read more…

AMD MI3000A

How AMD May Get Across the CUDA Moat

October 5, 2023

When discussing GenAI, the term "GPU" almost always enters the conversation and the topic often moves toward performance and access. Interestingly, the word "GPU" is assumed to mean "Nvidia" products. (As an aside, the popular Nvidia hardware used in GenAI are not technically... Read more…

Shutterstock 1606064203

Meta’s Zuckerberg Puts Its AI Future in the Hands of 600,000 GPUs

January 25, 2024

In under two minutes, Meta's CEO, Mark Zuckerberg, laid out the company's AI plans, which included a plan to build an artificial intelligence system with the eq Read more…

Google Introduces ‘Hypercomputer’ to Its AI Infrastructure

December 11, 2023

Google ran out of monikers to describe its new AI system released on December 7. Supercomputer perhaps wasn't an apt description, so it settled on Hypercomputer Read more…

China Is All In on a RISC-V Future

January 8, 2024

The state of RISC-V in China was discussed in a recent report released by the Jamestown Foundation, a Washington, D.C.-based think tank. The report, entitled "E Read more…

Intel Won’t Have a Xeon Max Chip with New Emerald Rapids CPU

December 14, 2023

As expected, Intel officially announced its 5th generation Xeon server chips codenamed Emerald Rapids at an event in New York City, where the focus was really o Read more…

IBM Quantum Summit: Two New QPUs, Upgraded Qiskit, 10-year Roadmap and More

December 4, 2023

IBM kicks off its annual Quantum Summit today and will announce a broad range of advances including its much-anticipated 1121-qubit Condor QPU, a smaller 133-qu Read more…

  • arrow
  • Click Here for More Headlines
  • arrow
HPCwire